BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to “Buy” by ValuEngine

ValuEngine upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a hold rating to a buy rating in a research note published on Wednesday morning, ValuEngine reports.

Other equities research analysts have also issued reports about the stock. Zacks Investment Research lowered shares of BioCryst Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, August 8th. BidaskClub raised shares of BioCryst Pharmaceuticals from a strong sell rating to a sell rating in a report on Wednesday, August 28th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $9.08.

BCRX traded down $0.01 during trading on Wednesday, reaching $2.70. 753,340 shares of the company traded hands, compared to its average volume of 1,499,211. The company has a debt-to-equity ratio of 2.38, a quick ratio of 1.43 and a current ratio of 1.44. BioCryst Pharmaceuticals has a 12-month low of $2.49 and a 12-month high of $9.95. The firm has a fifty day simple moving average of $2.90 and a 200 day simple moving average of $4.74. The company has a market cap of $298.18 million, a P/E ratio of -2.76 and a beta of 1.95.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). BioCryst Pharmaceuticals had a negative net margin of 1,091.44% and a negative return on equity of 371.33%. The company had revenue of $1.45 million for the quarter, compared to analysts’ expectations of $2.52 million. As a group, sell-side analysts expect that BioCryst Pharmaceuticals will post -1.23 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of BCRX. SG Americas Securities LLC bought a new position in shares of BioCryst Pharmaceuticals during the 1st quarter valued at approximately $169,000. DekaBank Deutsche Girozentrale boosted its position in shares of BioCryst Pharmaceuticals by 22.2% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 38,500 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 7,000 shares during the last quarter. Federated Investors Inc. PA boosted its position in shares of BioCryst Pharmaceuticals by 78.7% during the 1st quarter. Federated Investors Inc. PA now owns 779,406 shares of the biotechnology company’s stock valued at $6,344,000 after acquiring an additional 343,269 shares during the last quarter. ClariVest Asset Management LLC boosted its position in shares of BioCryst Pharmaceuticals by 1.6% during the 1st quarter. ClariVest Asset Management LLC now owns 234,898 shares of the biotechnology company’s stock valued at $1,913,000 after acquiring an additional 3,700 shares during the last quarter. Finally, Franklin Street Advisors Inc. NC boosted its position in shares of BioCryst Pharmaceuticals by 45.5% during the 1st quarter. Franklin Street Advisors Inc. NC now owns 64,000 shares of the biotechnology company’s stock valued at $521,000 after acquiring an additional 20,000 shares during the last quarter. Hedge funds and other institutional investors own 90.73% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Featured Article: Accumulation/Distribution

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.